safinamide (Xadago)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

  • severe liver problems[1]

Dosage

  • start 50 mg PO QD
  • may increase to 100 mg PO QD after 2 weeks if clinically indicated

Adverse effects

Drug interactions

Mechanism of action

Clinical trials

  • on time without troublesome dyskinesia longer with safinamide than with placebo[2] (manufacturer-supported phase III study)

More general terms

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Brooks M FDA Okays Safinamide (Xadago) for Parkinson's Disease Medscape. March 21, 2017 http://www.medscape.com/viewarticle/877524
    FDA News Release. March 21, 2017 FDA approves drug to treat Parkinson's Disease. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm547852.htm
    Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
    U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
  2. 2.0 2.1 Schapira AHV et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson Disease and motor fluctuations: A randomized clinical trial. JAMA Neurol 2017 Feb 1; 74:216 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27942720
  3. Borgohain R, Szasz J, Stanzione P et al Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord. 2014 Feb;29(2):229-37. Epub 2013 Dec 9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24323641 Free PMC Article

Database